FDA bans products from India's Canton; Sibelius resigns;

@FiercePharma: Natco looking to block Indian patent for Gilead's Sovaldi. Story | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read marketing story: Sanofi aims for outcomes with new Chief Patient Officer. More | Follow @TracyStaton

@EricPFierce: RT from FiercePharma: AbbVie partners with Arabio for production in Saudi Arabia. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Our latest issue of FierceVaccines. More | Follow @CarlyHFierce

> The FDA has issued an import alert, banning products from Canton Laboratories in India after issuing a warning letter to one of its plants last month. Story

> Health and Human Services (HHS) Secretary Kathleen Sebelius is resigning, leading many to speculate on the future of the Affordable Care Act. News

> In a Phase II trial, Gilead's ($GILD) Sovaldi performed well in hepatitis patients with severe liver disease. More

> Pfizer ($PFE) CEO Ian Read was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) Friday, while Merck ($MRK) CEO Kenneth Frazier became chairman-elect of the PhRMA board of directors and George Scangos, CEO of Biogen Idec, a board treasurer. Release

> Georgia Governor Nathan Deal is working on a way to legalize medical marijuana for treatment of children with seizure disorders after a bill to do so died in the Georgia legislature last month. Story

Medical Device News

@FierceMedDev: Boston Scientific launches a new clinical trial of its deep brain stimulation device. More | Follow @FierceMedDev

@VarunSaxena2: Deerfield bets on robotic surgery with OMNIlife science deal. Article | Follow @VarunSaxena2

@EmilyWFierce: "Molecular tweezers" could help prevent degenerative diseases like Alzheimer's or Parkinson's, say scientists at UCLA. Article | Follow @EmilyWFierce

@MichaelGFierce: ICYMI: 'Computer' made with DNA nanorobots delivers compounds in live cockroach. More from FierceDrugDelivery | Follow @MichaelGFierce

> Mainstay Medical sets its sights on a €23 million IPO. Story

> Smith & Nephew puts up $12M to clear the way for its $1.7B ArthroCare deal. More

> AngioDynamics boosts revenue as its turnaround stays on track. News

Biotech News

@FierceBiotech: Chimerix CEO Moch steps down after compassionate-use controversy. More | Follow @FierceBiotech

@JohnCFierce: Bayer backs VC fund, FBI calls Russian VCs thieves, Oryzon and Serendex plan IPOs. EuroBiotech Report | Follow @JohnCFierce

@DamianFierce: As Gilead gets pilloried over pricing, Bristol-Myers Squibb (Report) and Merck (Report) creep up in hep C. | Follow @DamianFierce

@EmilyMFierce: 'Not messing around': Ill. health official taking infectious tuberculosis patient to court. Story | Follow @EmilyMFierce

> Three IPO hopefuls look to squeeze out $144M as biotech gets bearish. News

> VCs gamble $45M on PhII pain drug, new U.S. base for Spinifex. More

> AbbVie angles for hep C spotlight as Merck shoulders to the front. Story

And Finally... Milk consumption may slow the progression of knee arthritis, a study found. More (sub. req.)


Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.